Characteristics of patients with B-cell NHL treated with lenalidomide
| Characteristic . | Single-agent Len . | Len + biologics . | Len + Chemo . |
|---|---|---|---|
| Median age (range), y | 66 (21-89) | 65 (24-89) | 68 (22-94) |
| Median stage at treatment initiation | 4 | 4 | 4 |
| Median prior therapies (range) | 3 (0-13) | 3 (0-7) | 0 (0-7) |
| Median performance status (% performance status 0-1) | 0-1 (88) | 0-1 (67) | 0-1 (87) |
| No. of patients | 698 | 357 | 378 |
| DLBCL, % | 21 | 15 | 54 |
| Follicular, % | 13 | 27 | 10 |
| MCL, % | 54 | 53 | 26 |
| Other lymphoma subtype, % | 11 | 5 | 10 |
| Untreated, % | 2 | 15 | 57 |
| Relapsed/Refractory, % | 98 | 85 | 43 |
| Male/Female, % | 70/30 | 72/28 | 65/45 |
| Total cycles received | 4249 | 3387 | 2466 |
| Mean cycles per patient | 6 | 12 | 7 |
| Characteristic . | Single-agent Len . | Len + biologics . | Len + Chemo . |
|---|---|---|---|
| Median age (range), y | 66 (21-89) | 65 (24-89) | 68 (22-94) |
| Median stage at treatment initiation | 4 | 4 | 4 |
| Median prior therapies (range) | 3 (0-13) | 3 (0-7) | 0 (0-7) |
| Median performance status (% performance status 0-1) | 0-1 (88) | 0-1 (67) | 0-1 (87) |
| No. of patients | 698 | 357 | 378 |
| DLBCL, % | 21 | 15 | 54 |
| Follicular, % | 13 | 27 | 10 |
| MCL, % | 54 | 53 | 26 |
| Other lymphoma subtype, % | 11 | 5 | 10 |
| Untreated, % | 2 | 15 | 57 |
| Relapsed/Refractory, % | 98 | 85 | 43 |
| Male/Female, % | 70/30 | 72/28 | 65/45 |
| Total cycles received | 4249 | 3387 | 2466 |
| Mean cycles per patient | 6 | 12 | 7 |
Chemo, chemotherapy; Len, lenalidomide.